Cantor Fitzgerald Equities Analysts Lift Earnings Estimates for Adlai Nortye Ltd. (NASDAQ:ANL)

Adlai Nortye Ltd. (NASDAQ:ANL) – Stock analysts at Cantor Fitzgerald increased their FY2024 earnings per share estimates for shares of Adlai Nortye in a report issued on Tuesday, April 23rd. Cantor Fitzgerald analyst L. Chen now anticipates that the company will post earnings per share of ($2.41) for the year, up from their prior estimate of ($2.50). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Adlai Nortye’s current full-year earnings is ($2.90) per share.

Adlai Nortye Stock Down 0.7 %

Shares of NASDAQ ANL opened at $13.46 on Thursday. The business has a fifty day simple moving average of $9.33 and a two-hundred day simple moving average of $9.31. Adlai Nortye has a twelve month low of $7.11 and a twelve month high of $19.30.

Institutional Investors Weigh In On Adlai Nortye

A hedge fund recently raised its stake in Adlai Nortye stock. Cantor Fitzgerald L. P. raised its position in shares of Adlai Nortye Ltd. (NASDAQ:ANL) by 128.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 40,310 shares of the company’s stock after purchasing an additional 22,644 shares during the period. Cantor Fitzgerald L. P. owned about 0.11% of Adlai Nortye worth $362,000 as of its most recent filing with the Securities & Exchange Commission. 35.21% of the stock is owned by hedge funds and other institutional investors.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.